RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.47%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$563M
AUM Growth
+$563M
(+12%)
Cap. Flow
+$42.6M
Cap. Flow
% of AUM
7.57%
Top 10 Holdings %
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$13.1M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11.9M |
| 3 |
Biogen
BIIB
|
$10.2M |
| 4 |
CELG
Celgene Corp
CELG
|
$7.79M |
| 5 |
ENDP
Endo International plc
ENDP
|
$5.85M |
Top Sells
| 1 |
Alkermes
ALKS
|
$11.6M |
| 2 |
STJ
St Jude Medical
STJ
|
$9.9M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$6.45M |
| 4 |
Labcorp
LH
|
$3.91M |
| 5 |
Perrigo
PRGO
|
$3.72M |
Sector Composition
| 1 | Healthcare | 93.53% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $26M | 4.63% | 223,082 +102,082 | +84% | +$11.9M |
|
2
Gilead Sciences
GILD
$140B
| $20M | 3.56% | 240,000 +60,000 | +33% | +$5.01M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $19.6M | 3.49% | 199,000 +79,000 | +66% | +$7.79M |
|
|
4
Biogen
BIIB
$19.4B
| $19.3M | 3.44% | 80,000 +42,000 | +111% | +$10.2M |
|
5
Eli Lilly
LLY
$657B
| $18.5M | 3.29% | 235,000 +40,000 | +21% | +$3.15M |
|
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $17.3M | 3.07% | 49,500 +37,500 | +313% | +$13.1M |
|
7
Incyte
INCY
$16.5B
| $13.6M | 2.41% | 170,000 | – | – |
|
8
Pfizer
PFE
$141B
| $13.2M | 2.34% | 375,000 -100,000 | -21% | -$3.52M |
|
9
Cigna
CI
$80.3B
| $12.7M | 2.25% | 99,000 +30,000 | +43% | +$3.84M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $12M | 2.13% | 52,000 +10,000 | +24% | +$2.31M |
|
11
UnitedHealth
UNH
$281B
| $12M | 2.13% | 85,000 +25,000 | +42% | +$3.53M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11.7M | 2.07% | 150,000 -40,000 | -21% | -$3.11M |
|
13
CVS Health
CVS
$92.8B
| $11.5M | 2.04% | 120,000 +15,000 | +14% | +$1.44M |
|
|
ABMD
14
DELISTED
Abiomed Inc
ABMD
| $11.5M | 2.04% | 105,000 -20,000 | -16% | -$2.19M |
|
15
Medtronic
MDT
$119B
| $11M | 1.96% | 127,000 -10,000 | -7% | -$868K |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $10.8M | 1.92% | 195,000 +70,000 | +56% | +$3.88M |
|
17
Bristol-Myers Squibb
BMY
$96B
| $10.1M | 1.79% | 137,000 -5,000 | -4% | -$368K |
|
|
ENDP
18
DELISTED
Endo International plc
ENDP
| $9.9M | 1.76% | 635,200 +375,200 | +144% | +$5.85M |
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $9.89M | 1.76% | 70,000 +40,000 | +133% | +$5.65M |
|
20
Amgen
AMGN
$155B
| $9.36M | 1.66% | 61,500 +16,500 | +37% | +$2.51M |
|
|
ESRX
21
DELISTED
Express Scripts Holding Company
ESRX
| $8.79M | 1.56% | 116,000 +10,000 | +9% | +$758K |
|
22
Zimmer Biomet
ZBH
$21B
| $8.55M | 1.52% | 71,000 -20,000 | -22% | -$2.41M |
|
|
AET
23
DELISTED
Aetna Inc
AET
| $8.18M | 1.45% | 67,000 | – | – |
|
|
CPHD
24
DELISTED
Cepheid Inc
CPHD
| $8M | 1.42% | 260,000 +110,000 | +73% | +$3.38M |
|
25
Centene
CNC
$14.3B
| $7.97M | 1.42% | 111,712 -30,000 | -21% | -$2.14M |
|